Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07429487 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer

Study acronym: WATCH AND ACT
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 8 of 8 entries
    • Site details revised
  2. Notable Start date: Jun 15, 2026 to Sep 15, 2026v2
  3. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
5,418 trials monitored
See 296 trials at risk
3,394 trials monitored
See 159 trials at risk
1,739 trials monitored
See 106 trials at risk
and 2 more diseases
A single-center, randomized (1:1) open-label, prospective, stratified study with two parallel arms, designed to evaluate adherence to the adapted physical activity (APA) program for patients participating in an APA program and to compare changes in fatigue at 3 months in patients who have completed adjuvant systemic chemotherapy for cancer and are participating in an APA program.
Trial Details
NCT Number NCT07429487
Lead Sponsor Centre Antoine Lacassagne
Collaborators: Centre Hospitalier Universitaire de Nice
Conditions
(from sponsor)
Breast Cancer, Colorectal Cancer, Ovarian Adenocarcinoma, Pancreatic Cancer, Gastric Adenocarcinoma
Related terms Breast Neoplasms, Colorectal Neoplasms, Fatigue, Pancreatic Neoplasms
Enrollment 98 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov